{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.6","upperLimit":"93.9","value":"86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"Objective Response Rate by Independent Review Group","type":"PRIMARY","unitOfMeasure":"percent of participants"}